Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade

Breast Cancer Research and Treatment

Volumn 96, Issue 2, 2006, Pages 147-157

  Wu, Kendall ^a   DuPré, Elizabeth ^a   Kim, Heetae ^a   Tin U, Caesar K ^a   Bissonnette, Reid P ^b   Lamph, William W ^b   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Breast cancer; Breast cells; Chemoprevention; Receptor selective; Retinoids

Indexed keywords

ALITRETINOIN; BEXAROTENE; CYCLIN D1; CYCLIN D3; ESTROGEN RECEPTOR; LGD 100268; RETINOBLASTOMA PROTEIN; RETINOID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; G1 PHASE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 33645220720     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9071-1     Document Type: Article

References (38)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
2. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, Norton L, Nickelsen T, Bjarnason N, Morrow M, Lippman M, Black D, Glusman J, Costa A, Jordan V: The effect of raloxifene on risk of breast cancer in postmenopausal women - results from the MORE randomized trial. J Amer Med Assoc 281: 2189-2197, 1999
3. Wu K, Kim H, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH: 9-cis retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T-antigen transgenic mice. Clin Cancer Res 6: 3696-3704, 2000
4. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11: 467-474, 2002
5. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonnette R, Brown PH: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376-6380, 2002
6. Zhao Z, Zhang Z-P, Soprano DR, Soprano KJ: Effect of 9-cis-retinoic acid on growth and RXR expression in human breast cancer cells. Exp Cell Res 219: 555-561, 1995
7. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Wilson H, Miller J: 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 54: 6549-6556, 1994
8. Kizaki M, Dawson MI, Heyman R, Elstner E, Morosetti R, Pakkala S, Chen D-L, Ueno H, Chao W-r , Morikawa M, Ikeda Y, Heber D, Pfahl M, Koeffler HP: Effects of novel retinoid X receptor-selective ligands on myeloid leukemic differentiation and proliferation in vitro. Blood 5: 1977-1984, 1996
9. Gudas L, Sporn MB, Roberts AB: Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry, and Medicine. 2nd edition, Raven Press, Ltd, New York 1994 , pp 443-520
10. Roberts A, Sporn M: Cellular biology and biochemistry of retinoids. In: Sporn M, Roberts A, Goodman D (eds) The Retinoids. Academic Press, Orlando, FL, 1984, pp 209-284, 443-520
11. Mangiarotti R, Danova M, Alberici R, Pellicciari C: All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. Br J Cancer 77: 186-191, 1998
12. Seewaldt VL, Kim J-H, Caldwell LE, Johnson BS, Swisshem K, Collins SJ: All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 8: 631-641, 1997
13. Toma S, Isnaardi L, Riccardi L, Bollag W: Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18: 935-942, 1998
14. Toma S, Isnardi L, Raffo P, Dastoli G, DeFrancisci E, Riccardi L, Palumbo R, Bollag W: Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70: 619-627, 1997
15. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM: Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res 234: 293-299, 1997
16. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 83: 841-850, 1995
17. Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W, Toma S: Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 20: 1535-1543, 2000
18. Yang L, Kim H, Munoz-Medellin D, Reddy P, Brown PH: Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res 57: 4652-4661, 1997
19. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, Sporn MB: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54: 4614-4617, 1994
20. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis retinoic acid. J Natl Cancer Inst 88: 123-125, 1996
21. Miller VA, Rigas JR, Benedetti FM, Verret AL, Tong WP, Kris MG, Gill GM, Loewen GR, Truglia JA, Ulm EH, Warrell RP Jr: Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 2: 471-475, 1996
22. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56: 5566-5570, 1996
23. Teixeira C, Pratt MA: CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 11: 1191-1202, 1997
24. Seewaldt VL, Dietze EC, Johnson BS, Collins SJ, Parker MB: Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. Cell Growth Differ 10: 49-59, 1999
25. Fontana JA, Rishi AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia 16: 463-472, 2002
26. Mariotti A, Marcora E, Bunone G, Costa A, Veronesi U, Pierotti MA, Della Valle G: N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86: 1245-1247, 1994
27. Wang TT, Phang JM: Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 107: 65-71, 1996
28. Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R: Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Int J Cancer 70: 484-487, 1997
29. Fanjul AN, Piedrafita FJ, AL-Shamma H, Pfahl M: Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res 58: 4607-4610, 1998
30. Herbert BS, Sanders BG, Kline K: N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer 34: 121-132, 1999
31. Yang L, Ostrowski J, Reczek P, Brown P: The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene 20: 8025-8035, 2001
32. Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P, Pfahl M: Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol Endocrinol 7: 1347-1356, 1993
33. Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH: Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat 56: 277-291, 1999
34. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z: Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 94: 5826-5830, 1997
35. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH: The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65: 3462-3469, 2005
36. Fontana JA: Interaction of retinoids, tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 55: 136-144, 1987
37. Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA, Sporn MB: Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LGD100268. Clin Cancer Res 8: 3270-3275, 2002
38. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118, 1999